Shenyun Medical
合源医疗
Shenyun Medical (上海合源医疗, United InnoMed) is a Shanghai-based medical device company focused on heart failure management, founded and led by CEO Wang Li . In April 2025, the company closed a funding round exceeding RMB 100 million, co-led by Dalton Venture and Dragonstone Capital, with follow-on participation from existing investor Lilly Asia Ventures . The proceeds are earmarked for clinical development and registration of its core pipeline products . Beyond this financing, elsewhere's corpus does not cover the company's specific technologies or market position in depth.
AI-generated — may contain errors, please verify.
Coverage
A Decade of Dalton, Igniting a New Chapter of Intelligence | Dalton Venture's 2025 Annual Partners Meeting and 10th Anniversary Forum Concludes Successfully
Together, Toward the Brilliance and Distant Horizons of the Next Decade
Riding the Wind, Breaking Boundaries — Tides Surge in Hong Kong | Dalton Venture 2025 CEO Summit Successfully Concludes
At the intersection of technological revolution and industrial transformation, what should be the starting point for the globalization of the life sciences industry? Where should mainland Chinese healthcare innovators set their first foothold for overseas expansion? Against a backdrop of intensifying international competition and sustained policy tailwinds, is Hong Kong — a city that blends international perspective with institutional advantages — emerging as the bridge for tech ventures to reach the world?
Heyuan Medical Closes Funding Round Exceeding RMB 100 Million, Dalton Venture Co-Leads Investment, Multiple Breakthrough Technologies Empower Heart Failure Management | Dalton Venture News
Recently, **Shanghai-based United InnoMed® announced the completion of a new funding round exceeding 100 million RMB**. The round was **jointly led by Dalton Venture and Dragonstone Capital**, with follow-on investments from Yinglian Health Fund and Tianrui Fengnian Capital. Existing investor Lilly Asia Ventures continued to increase its stake. **The proceeds will be primarily used for the R&D and registration clinical trials of multiple core pipeline products.**
